INmune Bio raises $4.5M after Alzheimer's trial setback

What's the deal? INmune Bio, a Boca Raton-based biotechnology company focused on inflammation and immunology, has priced a $4.5 million offering, selling 3,000,000 shares of common stock to a single healthcare-focused institutional investor. A concurrent private placement adds warrants for up to 3,000,000 more shares at an exercise price of $1.65, exercisable six months after issuance and expiring in five and a half years.

The terms: A.G.P./Alliance Global PartnersDealroom has a profile for this one. Try Dealroom → acted as sole placement agent. The deal was set to close on or about October 29, 2026. INmune plans to use the proceeds for working capital and general corporate purposes.

Why now? The raise follows a sharp setback. INmune's Phase 2 MINDFuL Alzheimer's trial missed its primary cognitive endpoint across the overall study population, though the company flagged more favourable signals in a smaller inflammation-biomarker subgroup.

What's the endgame? The company reported $18.4 million in cash at June 30 and had estimated its runway extended into early 2027. This financing adds a modest buffer as it weighs next steps for lead program XPro and advances other work, including its late-stage CORDStrom cell platform.

What could go wrong? The deal brings dilution as well as cash: 3 million shares now, plus warrants for 3 million more. With its lead program under a cloud, that is a meaningful trade-off for a relatively small sum.

The signal: This is less a major biotech financing than a near-term capital top-up amid heightened uncertainty over INmune's lead program — the kind of small, dilutive raise clinical-stage companies turn to when a key readout disappoints.

Read more: marketscreener.com

Image credit: Generated with Gemini